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Background: Concomitant cocaine use is a major problem in clinical practice in methadone maintenance
treatment (MMT) and may interfere with successful treatment. Data from European methadone populations is
sparse. This register-based study sought to explore the association between prescribed methadone dose and
concomitant cocaine and heroin use in the methadone population of Basel City.
Methods: The study included 613 methadone patients between April 1, 2003 and March 31, 2004. Anonymized
data was taken from the methadone register of Basel City. For analysis of the prescribed methadone dose
distribution, the patient sample was split into three methadone dosage groups: a low dose group (LDG)
(n = 200; < 60 mg/day), a medium dose group (MDG) (n = 273; 60 to 100 mg/day), and a high dose group (HDG)
(n = 140; > 100 mg/day). Concomitant drug use was based on self-report.
Results: Analysis showed a significant difference in self-reported cocaine use between groups (p < 0.001). Patients
in the LDG reported significantly fewer cocaine consumption days compared to the MDG (p < 0.001) and the HDG
(p < 0.05). Patients in the HDG reported significantly fewer heroin consumption days than those in the LDG
(p < 0.01) and the MDG (p < 0.001). In logistic regression analysis, cocaine use was significantly associated with
heroin use (OR 4.9).
Conclusions: Cocaine use in methadone patients may be associated with heroin use, which indicates the
importance of prescribing appropriate methadone dosages in order to indirectly reduce cocaine use.
Keywords: Cocaine use, Methadone dose, Methadone maintenance treatment, Opioid dependenceIntroduction
Opioid dependence is a serious chronic illness with a
multitude of somatic and psychosocial risks and which
in most cases requires long-term treatment [1-4].
Methadone maintenance treatment (MMT) is an effect-
ive treatment for opioid dependent patients, particularly
when given with other psychosocial services [1-7]. MMT
has proven beneficial in reducing illicit opioid use
and associated harms, and is considered to be the first
line treatment [2,3,8,9] Nevertheless, some methadone* Correspondence: marcus.baumeister@pbl.ch
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article, unless otherwise stated.patients continue to abuse heroin and other non-opiate
drugs, such as cocaine, during treatment.
In Switzerland, the prevalence of opioid dependence
was 0.9% in 2012 (men 1.6%, women 0.3%) [10] and co-
caine has been used by approximately 4.1% of citizens
aged between 15 and 64 years at least once in their lives
[11]. Prescription of methadone for opioid dependence
has been regulated by federal and state laws since 1975.
Approximately 17,000 patients in Switzerland are on
opioid substitution treatment; this number has been
nearly constant since 2000. Several medications are used
for maintenance treatment in Switzerland, including full
μ-receptor agonists (e.g. oral methadone and slow re-
lease morphine, oral and intravenous diacetylmorphine),
and the partial μ-receptor agonist and κ-receptortral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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methadone (90%). MMTs are covered by health insur-
ance and are provided by general practitioners (GPs)
and specialized centers [6]. Inclusion criteria for entering
a MMT are opioid dependence, being at least 18 years of
age, a positive toxicology test for heroin use, and failure
in previous abstinence-oriented treatments. The pre-
scribed and administered methadone is a 2% racemic
methadone hydrochloride solution. In clinical practice,
individualised treatment plans are developed and metha-
done doses are prescribed on the basis of clinical im-
pression, according to Swiss recommendations [13].
Basel City has 200,000 inhabitants, with approximately
2000 heroin users. Most patients are treated in special-
ized centers and one third in an office-based setting. In
Basel City, the average prescribed methadone dose has
increased over the past two decades from 59 ± 31 mg/
day [14] to 74 ± 47 mg/day [6].
The tendency toward higher methadone doses has
been supported by randomised clinical trials [15-18] and
observational studies [19-26]. While MMT has been
demonstrated to be an effective treatment for opioid de-
pendence, its impact on the treatment outcome of co-
caine abuse is not as clear. There is some evidence that
patients abusing cocaine during MMT are more likely to
drop out [27,28] and present a higher risk profile regard-
ing HIV and psychological disturbances [29], as well as
higher heroin use [20]. A positive effect of MMT on
concomitant cocaine use was observed in 5 observa-
tional studies [30-35], 1 meta-analysis [17] and 1 RCT
[36]. On the other hand, a mild effect was found in 2 ob-
servational studies [37,38] and no effect in 2 observa-
tional studies [32,39] and 2 RCTs [40,41]. There have
been few studies on the influence of different methadone
dose levels and its association with concurrent cocaine
use. Castells et al. [42] found no effect on cocaine ab-
stinence at methadone doses > 50 mg/d, as did Kennedy
et al. [41] in an RCT at methadone doses > 100 mg/d.
Nevertheless, Peles et al. [36] found an effect on cocaine
use in MMT at methadone doses > 100 mg/d. Data from
European methadone populations is sparse.
This register-based study sought to explore the associ-
ation between different prescribed methadone dose
levels and concomitant cocaine and heroin use in the
methadone population of Basel City between April 1,
2003 and March 31, 2004. We were especially interested
in the effect of higher methadone doses on concomitant
cocaine use, because not enough is known on this topic.
We hypothesised that patients with prescribed metha-
done doses > 100 mg/day would have better treatment
outcomes. To answer these research questions, we split
the sample into three subsamples. Methadone dosage
groups were defined according to a National Institutes
of Health (NIH) expert panel that has stated that a dailymethadone dose of at least 60 mg is best practice in
methadone maintenance [43]. The dose groups were a
low dose group (LDG) (10 mg/day to 59 mg/day), a
medium dose group (MDG) (60 to 100 mg/day), and a
high dose group (HDG) (101 mg/day to 260 mg/day).
Methods
Subjects
All data was taken from the methadone register of the
health authorities of Basel City, which was discontinued
in 2004. Data had been collected since 1995. The data
collection and evaluation are in accordance with the data
protection law of the Canton of Basel City and were ap-
proved by the local ethics committee “Ethikkommission
beider Basel EKBB” Hebelstrasse 53 CH-4056 Basel
Switzerland www.ekbb.ch (ethical review committee of
both Basel (Basel-City and Basel-Countryside)). As stip-
ulated by legislation, prescribing treatment providers in
Basel City are required to submit a registration form to
the health authorities each time a heroin-dependent pa-
tient begins and ends MMT. The form collects informa-
tion about methadone patients and their treatment. For
monitoring purposes, methadone prescribers were fur-
ther invited until 2004 to provide anonymized patient
and treatment data to the register every 12 months by
means of a 2-page questionnaire. Methadone prescribers
were instructed to carry out the interviews within one
month and send them back to the health authorities.
This structured questionnaire contained a core of ques-
tions about gender, nationality, marital status, educa-
tional level, work situation, age at first heroin and
cocaine use, treatment facility [specialized centers, office
based treatment], year entering MMT, currently pre-
scribed methadone dose (mg/d), prescribed psychiatric
comedication, allowed take-home days per week (0–7
days), number of consultations in the past 6 months,
and self-reported substance use (heroin, cocaine, alcohol,
cannabis) during the previous 30 days (according to the
European Addiction Severity index [44]). The present
evaluation includes data of MMT patients from April 1,
2003 to March 31, 2004. Throughout that period, three
clinics (two public, one private) and 81 office-based
practitioners conducted MMT in Basel City.
Procedures and statistical analyses
Anonymised data from prescription for opioids were col-
lected and analysed by the Addiction Research Center of
the Hospital of the University of Basel. A total of 974 pa-
tients were surveyed. The response rate was 91% (n =
886). Overall 273 out of 886 patients had to be excluded
from the statistical analyses by the study investigators
due to missing variables (e.g. gender, age [n = 12], daily
prescribed methadone dosage [n = 17], self-reported
illicit drug use in the past 30 days [n = 78], and length of
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excluded from the analyses, because they had been given
a prescription for opioid substitution treatment other
than with methadone (buprenorphine, n = 45; morphine,
n = 23), and 19 patients were excluded because they
were tapering methadone to end MMT. The final sam-
ple included 613 patients and was split into three metha-
done dose groups (LDG, MDG and HDG).
Dependent variables were concomitant cocaine use
(consumption days) and concomitant heroin use (con-
sumption days). Continuous (interval-scaled) data were
analyzed by one way analysis of variance, and post-hoc
tests (Duncan Scheffé’s); categorical data were analyzed
by χ2 statistics and non-parametric tests (Kruskal-Wallis
test, Mann–Whitney test).
To model the determinants of cocaine use in MMT, we
used a backward fitting procedure that applied likelihood
ratio tests to develop a binary logistic regression model,
with cocaine use (coded as a dichotomous variable) as the
dependent variable. Initially we included the following pre-
dictor variables, that were either associated in bivariate
analysis or known from literature: age (years); gender (fe-
male); employment status (yes = 1); office-based settings
(yes = 1); days with take-home (days); prescribed metha-
done dose group (low methadone dose as the reference
category); and concomitant heroin use (no = 0). Because of
a large number of missing values, we refrained from in-
cluding the variables route of administration, age at first
heroin and cocaine use. Data analyses were conducted
using SPSS (version 17, SPSS Inc, Chicago, IL). The level
of significance was set at p < 0.05.
Results
Socio-demographic characteristics
Of 613 methadone patients in MMT, 32.6% were in the
LDG (n = 200), 44.5% in the MDG (n = 273), and 22.8%Table 1 Sociodemographic characteristicsa
Variables Low dose group
(LDG) (n = 200)
Medium
(MDG) (
Gender, n (%) male 132 (66.0) 188 (68.9
Age, mean (SD), y 39.4 (±6.9) 38.4 (±6.
Nationality, n (%) Swiss 169 (86.2) 230 (86.5
Marital status, n (%) Married 24 (12.0) 28 (10.3)
Education, mean (SD), y 10.9 (±1.5) 10.9 (±1.
Employed, n (%)b 54 (29.0) 49 (18.8)
Age at first heroin use, mean (SD), yc 20.8 (±5.3) 19.2 (±4.
Age at first cocaine use, mean (SD), yd 22.3 (±6.9) 21.3 (±5.
aThe groups did not differ in any variable at the p < 0.05 level, except as noted.
bSignificant difference between patients in the LDG, MDG and HDG (Kruskal-Wallis-
patients in the LDG were significantly more often employed than patients in the M
cSignificant difference between patients in the LDG, MDG and HDG for age at first h
revealed that patients in the LDG started heroin use significantly later in their lives
dNo difference between the LDG, MDG and HDG for age at first cocaine use, but a
(trend, p = 0.054).in the HDG (n = 140). Patients were aged from 22 to
61 years (38.9 ± 6.6); two thirds were men (67.9%); 10.4%
were married; the mean years of education were 10.8 ±
1.6, and 20.6% were employed (see Table 1). Overall,
demographic characteristics did not differ between the
three methadone dosage groups, except for the variables
employment status and age at first heroin use, with a
significantly higher proportion of patients in the LDG
than in the MDG and HDG who were employed or who
had started using heroin significantly later in their lives
(see Table 1).
Clinical characteristics
Two thirds of the patients received their methadone in
specialized centers and prescribed mean methadone
doses differed significantly between groups (p < 0.001;
range: 10 to 260 mg/day; mean: 81.9 ± 46.7 mg/d) (see
Table 2). Two thirds of the patients had a prescribed
psychiatric comedication, with the HDG presenting the
highest proportion. Allowed methadone take-home days
per week also varied significantly between groups (p <
0.001). Patients in the HDG had significantly fewer
allowed take-home days than patients in the LDG (p <
0.001) but not those in the MDG (p > 0.05). Patients had
been in MMT for between 1 and 29 years (10.2 ± 4.7),
with significant differences between groups (p < 0.001).
Patients in the HDG had a significantly longer period in
MMT than the LDG (p < 0.001) but not the MDG (p >
0.05). Patients had had a mean of 6.4 ± 4.7 consultations
within the 6 months prior to the interview, with signifi-
cant differences between groups (p < 0.01). Patients in
the HDG had significantly more consultations than pa-
tients in the LDG (p < 0.01) and in the MDG (p < 0.05).
Patients reported a mean of 9.1 ± 12.1 days of alcohol
use in the past 30 days prior to the interview, with sig-
nificant differences between groups (p < 0.01). Patientsdose group
n = 273)
High dose group




) 96 (68.6) 416 (67.9) p > 0.05
4) 38.9 (±6.4) 38.9 (±6.6) p > 0.05
) 118 (84.9) 517 (86.0) p > 0.05
12 (8.6) 64 (10.4) p > 0.05
6) 10.6 (±1.6) 10.8 (±1.6) p > 0.05
17 (12.6) 120 (20.6) p < 0.001
3) 18.1 (±4.1) 19.5 (±4.7) p < 0.01
7) 19.7 (±4.3) 21.3 (±5.9) p > 0.05
Test; χ2 = 15.587; df = 2; p < 0.001). The Mann Whitney test revealed that
DG (Z = − 2.878; p < 0.01) or in the HDG (Z = −3.603; p < 0.001).
eroin use (ANOVA; F(2,277) = 6.206; p < 0.01). Post-hoc tests (Duncan Scheffé’s)
than patients in the MDG (p < 0.05) or in the HDG (p < 0.01).
trend for patients in the HDG to start cocaine use earlier in their lives
Table 2 Clinical characteristics
Variables Low dose group
(LDG) (n = 200)
Medium dose group
(MDG) (n = 273)
High dose group




Specialized centers, n (%)a 114 (57.0) 189 (69.2) 104 (74.3) 407 (66.4) p < 0.01
Methadone dose mg/ day, mean (SD)b 35.0 (±12.1) 81.3 (±14.8) 150.0 (±33.3) 81.9 (±46.6) p < 0.001
Prescribed comedication, n (%)c 77 (38.7) 164 (60.1) 108 (77.1) 349 (57.0) p < 0.001
Allowed take-home days per week, mean (SD)d 5.8 (±3.7) 5.1 (±3.2) 4.5 (±2.7) 5.2 (±3.3) p < 0.001
Length of stay in MMT, mean (SD), ye 9.3 (±4.5) 10.2 (±4.7) 11.3 (±4.8) 10.2 (±4.7) p < 0.001
No. of consultations within 6 months, mean (SD)f 5.9 (±4.2) 6.2 (±4.2) 7.7 (±6.7) 6.4 (±4.9) p < 0.01
Alcohol use in the past 30 days, mean (SD)g 7.4 (±11.1) 8.9 (±11.1) 11.8 (±13.3) 9.1 (±12.1) p < 0.01
Cannabis use in the past 30 days, mean (SD)h 8.5 (±12.1) 8.9 (±12.0) 11.8 (±13.3) 8.3 (±11.2) p > 0.05
Significance level p < 0.05.
aSignificant difference between patients in the LDG, MDG and HDG (Kruskal-Wallis test; χ2 = 12.782; df = 2; p < 0.01). The Mann Whitney test revealed that patients
in the LDG were significantly more often treated in office-based settings than patients in the MDG (Z = −2.736; p < 0.01) or in the HDG (Z = −3.266; p < 0.001).
bSignificant difference between patients in the LDG, MDG and HDG for prescribed methadone dose (ANOVA; F(2,610) = 1343.158; p < 0.001).
cSignificant difference between patients in the LDG, MDG and HDG (Kruskal-Wallis test; χ2 = 51.360; df = 2; p < 0.001). The Mann Whitney test revealed that
patients in the LDG had a significantly lower proportion of prescribed comedication than patients in the MDG (Z = −4.584; p < 0.001) or in the HDG
(Z = −6.990; p < 0.001).
dSignificant differences between patients in the LDG, MDG and HDG for allowed take-home methadone days per week (ANOVA; F(2,603) = 6.750; p < 0.001).
Post-hoc tests (Duncan Scheffé’s) revealed that patients in the HDG had significantly fewer take-home days than patients in the LDG (p < 0.001) but not in the
MDG (p > 0.05).
eSignificant differences between patients in the LDG, MDG and HDG for length of stay in MMT (ANOVA; F(2,611) = 7.734; p < 0.001). Post-hoc tests (Duncan Scheffé’s)
revealed that patients in the HDG had a significantly longer length of stay in MMT than patients in the LDG (p < 0.001) but not in the MDG (p > 0.05).
fSignificant differences between patients in the LDG, MDG and HDG for the number of consultations in the past 6 months (ANOVA; F(2,603) = 5.907; p < 0.01). Post-hoc
tests (Duncan Scheffé’s) revealed that patients in the HDG had significantly more consultations than patients in the LDG (p < 0.01) or in the MDG (p < 0.05).
gSignificant differences between patients in the LDG, MDG and HDG for alcohol use in the past 30 days (ANOVA; F(2,598) = 5.087; p < 0.01). Post-hoc tests (Duncan
Scheffé’s) revealed that patients in the HDG had significantly more alcohol consumption days than patients in the LDG (p < 0.01) but not in the MDG (p > 0.05).
hNo differences between patients in the LDG, MDG and HDG for cannabis use in the past 30 days (ANOVA; F(2,604) = 0.160; p > 0.05).
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sumption days than those in the LDG (p < 0.01), but not
than those in the MDG (p > 0.05). Patients reported a
mean of 8.3 ± 11.2 cannabis consumption days, with
non-significant group differences (see Table 2).
Concomitant cocaine use
Two thirds of the patients reported no concomitant co-
caine use at all in the 30 days prior to the interview (n =
394, 64.3%), and one third (n = 219, 35.7%) reported at
least 1 cocaine consumption day. In the LDG, 24.5%
(n = 49) reported cocaine use, in the MDG 42.9% (n =
117) and in the HDG 37.9% (n = 53). Patients reported a
mean of 2.8 ± 5.9 cocaine consumption days in the past
30 days. As shown in Figure 1, cocaine use differed sig-
nificantly between methadone dose groups (p < 0.001).
Patients in the LDG reported significantly fewer cocaine
consumption days than those in the MDG (p < 0.001)
and the HDG (p < 0.05). Patients treated in specialized
centers exhibited significantly higher proportions of
cocaine use (42.0% versus 23.3%; χ2 = 20.860; df = 1; p <
0.001), compared to patients in office-based settings.
Table 3 displays the results of binary logistic regres-
sion, with cocaine use as dependent variable. The odds
for taking cocaine greatly increased with concomitant
heroin use (OR 4.9). Furthermore, the odds for cocaine
use were increased in patients with prescriptions of both
medium and high methadone doses as compared to theLDG, and in those treated in specialized centers. The
odds for cocaine use decreased with the number of take-
home days. There was a tendency for lower odds in
employed patients, but did not reach statistical signifi-
cance. The other variables were not associated and thus
dropped from the model.
Concomitant heroin use
Two thirds of the patients reported no concomitant her-
oin use at all in the 30 days (n = 390, 63.6%), and one
third reported at least 1 heroin consumption day (n =
223, 36.4%). In the LDG, 37.0% (n = 74) reported heroin
use, in the MDG 41.8% (n = 114) and in the HDG 25.0%
(n = 35). Patients reported a mean of 2.8 ± 6.1 heroin
consumption days in the 30 days prior interview, with
significant differences between groups (p < 0.001) (see
Figure 2). Patients in the HDG reported significantly
fewer heroin consumption days compared to the LDG
(p < 0.01) and the MDG (p < 0.001). Patients treated in spe-
cialized centers exhibited significantly higher proportions of
concomitant heroin use than patients in office-based set-
tings (39.8% versus 29.6%; χ2 = 6.138; df = 1; p < 0.05).
Discussion
To our knowledge, this is the first register-based study
addressing the association between prescribed metha-
done dose levels and concomitant cocaine use among a
MMT population in Europe. The results show that self-
Figure 1 Self-reported cocaine use in 613 methadone-maintained patients during the 30 days prior to the interview differed significantly
with the prescribed methadone dose (mg/ day) (Kruskal-Wallis Test; χ2 = 15.963; df = 2; p < 0.001). Patients in the low dose group reported
significantly less cocaine use compared to the medium dose group (Mann–Whitney; Z = −3.915; p < 0.001) and the high dose group (Mann–Whitney;
Z = −2.058; p < 0.05).
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low in our study, with an average of 2.8 days in the past
30 days. Surprisingly, we found that patients in the LDG
had significantly fewer cocaine consumption days than
patients in the currently recommended dose range >





Methadone dosed Medium dose (60–100 mg/d)




Significance level set at p < 0.05.
aHosmer-Lemeshow test.
bP-value from Wald test with 1 degree of freedom.
cNo heroin use as reference category.
dLow-dose (<60 mg/d) as reference category.
eOffice-based setting as reference category.
fUnemployed/pension as reference category.that higher methadone doses would result in lower con-
comitant cocaine use. This finding supports the already
mentioned RCT of Kennedy et al. [41], which found that
individualized dosages of methadone of up to 190 mg/
day were not better than doses of 100 mg/day with
respect to concomitant heroin and cocaine use. Inbinary logistic regression analyses with cocaine use as
aine use (n = 574, χ2 = 2.53, p = 0.96a)
95% CI pb
Lower Upper
4.890 3.245 7.369 <0.0001
2.301 1.430 3.701 0.00059
2.085 1.190 3.656 0.011
1.881 1.185 2.986 0.0074
.822 .754 .897 <0.0001
.616 .364 1.043 0.071
Figure 2 Self-reported heroin use in 613 methadone-maintained patients during the 30 days prior to the interview differed significantly
with the prescribed methadone dose (mg/ day) (Kruskal-Wallis Test; χ2 = 13.326; df = 2; p < 0.001). Patients in the high dose group reported
significantly less heroin use compared to the low dose group (Mann–Whitney; Z = −2.723; p < 0.01) and the medium dose group (Mann–Whitney;
Z = −3.645; p < 0.001).
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high methadone doses (> 100 mg/day) may reduce co-
caine use in patients addicted to both heroin and co-
caine. However, these studies analyzed concomitant
cocaine use with urine analyses and were not only based
on self-report. Moreover, a recent Cochrane Review [17]
with 11 RCTs and 10 CPS, concluded that methadone
dosages ranging from 60 to 100 mg/day are more effect-
ive than lower dosages in retaining patients and reducing
concomitant cocaine and heroin use. Nevertheless, add-
itional studies are needed to examine the effects of higher
methadone dosage levels (> 100 mg/d) on concomitant
cocaine use.
The main finding in this study was that the most im-
portant factor predicting cocaine use in MMT was con-
comitant heroin use (OR 4.9), indicating that concomitant
heroin and cocaine use is common in a subgroup of
methadone patients. Furthermore, the odds for cocaine
use were increased in patients with prescriptions of both
medium (OR 2.3) and high (OR 2.1) methadone doses as
compared to the LDG. One explanation could be drawn
from the study results that patients in the LDG started co-
caine and heroin use later in their lives and seem be more
socially integrated, as the LDG is the group with signifi-
cantly more employed patients compared to the MDGand HDG. Furthermore, the LDG probably has less poly-
drug use and less concurrent medication for psychiatric
comorbidities. Patients in specialized centers were more
likely to have concomitant cocaine use (OR 1.9) than
patients in office-based settings. This result corresponds
to clinical practice, referring more instable patients to
specialized centers. The same accounts for the significant
result in less take-home medication days in patients with
more concomitant cocaine use (Table 3).
Study results show that 67.3% of the patients had
methadone doses prescribed in the recommended dose
range according to Swiss treatment guidelines [13], and
32.6% had prescribed doses below 60 mg/day. As expected,
we found that patients with prescribed methadone doses >
100 mg/day were associated with significantly fewer re-
ported heroin consumption days compared to the LDG
and MDG. Our findings are consistent with previous litera-
ture reviews [22] and observational studies [16,21,22,25]
and strongly support these. Overall, we found a low average
number of concomitant heroin consumption days in our
survey, with 2.8 consumption days in the 30 days prior
interview. Of concern, however, is the fact that patients in
the HDG had significantly more alcohol consumption
days than patients in the LDG. This supports the findings
of Gossop et al. [45] that patients maintained at high
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drinkers. The results in this register-based study also show
that most patients enrolled in MMT in Basel City stay in
treatment for long periods. Remarkably is the significantly
longer length of stay in treatment in the HDG compared to
the LDG.Limitations of the study
The results of this study were obtained through a retro-
spective analysis. Though this assures high external valid-
ity, prospective statements are not possible and causation
between methadone dose and concomitant substance use
cannot be drawn from a register-based study. Further-
more, this study does not provide information about pa-
tients staying for short periods in MMT (<1 year), nor
about patients who did not attend the interviews; this
might have led to underestimation of the amount of illicit
cocaine and heroin use. Another limitation is that con-
comitant drug use in MMT is based on self-reported data
and not verified by urine analyses. However, parallel drug
use does not usually lead to exclusion from MMT. We are
confident that self-reported drug use is quite similar to re-
sults from urine analyses. As Decker et al. observed, self-
reported cocaine use and urine analyses demonstrate good
concordance within treatment [46]. In a previous con-
trolled trial of methadone-maintained patients, we found
58% heroin-negative urine samples, compared to 63.6% in
this survey [12]. Furthermore, we had no information
about the kind, frequency, amount and route of adminis-
tration of concomitant drug use (e.g. injected heroin-
cocaine-benzodiazepine-“cocktail”) that could be related
to different methadone levels. Moreover, we had no infor-
mation about patients’ psychiatric co-morbidities which
could possibly influence concomitant cocaine and heroin
use. Finally it must be emphasized that the data are nearly
10 years old. On the other hand, recent reports on cocaine
use in Switzerland indicate stable cocaine prevalence in
the last decade [10].Conclusions
Despite these limitations, the following conclusions can
be drawn from the present study. Firstly, two thirds of
methadone prescriptions to opioid-dependent patients
were within the recommended range. Secondly, pre-
scribed methadone doses > 100 mg/day (HDG) were not
associated with significantly fewer cocaine consumption
days but with fewer heroin consumption days. Thirdly,
concomitant heroin use was the major risk factor for
cocaine use in MMT. This means that methadone pro-
viders are required to raise awareness for this issue by
prescribing appropriate methadone doses, in order to re-
duce concomitant heroin use directly and cocaine use
indirectly.Competing interests
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